Literature DB >> 9330989

Position paper on diagnostic criteria for Alzheimer disease.

L A Hansen1, R D Terry.   

Abstract

The lesions of Alzheimer disease (AD) consist of synapse and neuron loss associated with progressive deposition of amyloid as diffuse and neuritic plaques and accumulating tau abnormalities in the form of neurofibrillary tangles and neuropil threads. Diagnostic criteria for Alzheimer disease constitute arbitrary cut-off levels above which AD is deemed to exist, and below which lesser amounts of the same abnormalities are relegated to the nebulous category of aging changes. Demanding neocortical tangles for a diagnosis of AD sacrifices sensitivity on the altar of specificity, since, while such lesions usually represent an advanced stage in the orderly evolution of AD, lighter burdens of plaque-predominant AD pathology with tangles confined to the medial temporal lobe can cause dementia when associated with concomitant synapse loss. Such muted AD pathology typifies the Lewy body variant of AD, and it serves to segregate it from pure Lewy body disease. We endorse the semiquantitative neuritic-plaque based criteria from CERAD for routine diagnosis, and Braak staging with descriptive profiling of AD lesions in a research context.

Entities:  

Mesh:

Year:  1997        PMID: 9330989     DOI: 10.1016/s0197-4580(97)00073-0

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

1.  Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice.

Authors:  V Askanas; W K Engel
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

2.  Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease.

Authors:  Gali H Weissberger; Tamar H Gollan; Mark W Bondi; Daniel A Nation; Lawrence A Hansen; Douglas Galasko; David P Salmon
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

3.  Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates.

Authors:  E-J Bae; H-J Lee; Y-H Jang; S Michael; E Masliah; D S Min; S-J Lee
Journal:  Cell Death Differ       Date:  2014-03-14       Impact factor: 15.828

4.  Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer's Disease.

Authors:  Micaela Mitolo; Joanne M Hamilton; Kelly M Landy; Lawrence A Hansen; Douglas Galasko; Francesca Pazzaglia; David P Salmon
Journal:  J Int Neuropsychol Soc       Date:  2016-05-25       Impact factor: 2.892

5.  Amyloid precursor protein regulates netrin-1-mediated commissural axon outgrowth.

Authors:  Nicolas Rama; David Goldschneider; Véronique Corset; Jérémy Lambert; Laurent Pays; Patrick Mehlen
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

6.  Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies.

Authors:  Joanne M Hamilton; Kelly M Landy; David P Salmon; Lawrence A Hansen; Eliezer Masliah; Douglas Galasko
Journal:  Am J Geriatr Psychiatry       Date:  2012-09       Impact factor: 4.105

7.  Data-Driven vs Consensus Diagnosis of MCI: Enhanced Sensitivity for Detection of Clinical, Biomarker, and Neuropathologic Outcomes.

Authors:  Emily C Edmonds; Denis S Smirnov; Kelsey R Thomas; Lisa V Graves; Katherine J Bangen; Lisa Delano-Wood; Douglas R Galasko; David P Salmon; Mark W Bondi
Journal:  Neurology       Date:  2021-08-10       Impact factor: 11.800

8.  Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production.

Authors:  F C Lourenço; V Galvan; J Fombonne; V Corset; F Llambi; U Müller; D E Bredesen; P Mehlen
Journal:  Cell Death Differ       Date:  2009-01-16       Impact factor: 15.828

9.  Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies.

Authors:  Denis S Smirnov; Douglas Galasko; Steven D Edland; J Vincent Filoteo; Lawrence A Hansen; David P Salmon
Journal:  Neurology       Date:  2020-04-24       Impact factor: 11.800

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.